News & Updates
Filter by Specialty:
High flow nasal oxygen feasible in pulmonary rehabilitation of COPD patients
Use of high flow nasal oxygen (HFO) is feasible during early pulmonary rehabilitation for improving exercise capacity in chronic obstructive pulmonary disease (COPD) patients after an exacerbation, results of a pilot randomized controlled trial (RCT) have shown. Additionally, HFO has high patient acceptability.
High flow nasal oxygen feasible in pulmonary rehabilitation of COPD patients
15 Dec 2023
Baricitinib, ivermectin, favipiravir rank high among COVID-19 oral antivirals
Baricitinib, ivermectin, and favipiravir stood out in terms of efficacy in a network meta-analysis evaluating various novel oral antivirals for the treatment of COVID-19.
Baricitinib, ivermectin, favipiravir rank high among COVID-19 oral antivirals
15 Dec 2023
NPAR, NLR predict risk of death in COPD patients
Increased neutrophil-percentage-to-albumin ratio (NPAR) and neutrophil-to-lymphocyte ratio (NLR) appear predictive of mortality risks in community-dwelling adults with chronic obstructive pulmonary disease (COPD), suggests a US study.
NPAR, NLR predict risk of death in COPD patients
14 Dec 2023
BPaLM regimen continues to show benefit against rifampicin-resistant tuberculosis
In the treatment of patients with rifampicin-resistant tuberculosis, a 6-month oral regimen consisting of bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) is safe and efficacious and compares favourably with standard of care, as shown in the final data from the phase IIB-III TB-PRACTECAL study.
BPaLM regimen continues to show benefit against rifampicin-resistant tuberculosis
12 Dec 2023
Benralizumab appears superior to mepolizumab in severe eosinophilic asthma
Both mepolizumab and benralizumab are effective in improving the clinical outcomes of patients with severe eosinophilic asthma, as shown in a recent study. However, treatment with benralizumab appears to be better than mepolizumab in reducing exacerbations, improving forced expiratory volume, and depleting blood eosinophils.
Benralizumab appears superior to mepolizumab in severe eosinophilic asthma
12 Dec 2023
Amivantamab-based regimens may alter EGFR-mutant NSCLC treatment paradigm in Asia
Updates from two MARIPOSA trials presented at ESMO Asia 2023 underpin the potential of amivantamab-based regimens for the treatment of locally advanced or metastatic EGFR-mutated non-small cell lung cancer (EGFRm NSCLC) in Asian subgroups.